Water-Soluble Well-Defined Bifunctional Ferrocenyl Dendrimer with Anti-Cancer Activity

Autor(es)

Bertuzzi, Diego L. ; Braga, Carolyne B. ; Perli, Gabriel ; Ornelas, Catia

• Tipo de documento: Artigo Científico
• Fonte: European Journal of Inorganic Chemistry; v. 2022, n. 9, p. 6-pg., 2022-02-01.

Resumo

Combination of advantages of ferrocenyl compounds and multifunctional dendrimer scaffold afforded a water-soluble well-defined bifunctional dendrimer with polyamide backbone and thirty two termini: eighteen carboxylic acid groups and eighteen triazolylferrocenyl moieties. The structure of the new dendrimer was thoroughly characterized by nuclear magnetic resonance (NMR) spectroscopy, absorbance spectroscopy in the UV-vis, and MALDI-TOF mass spectrometry. The MALDI-TOF spectrum of the final dendrimer showed the [M](2+) ion peak at 4820.1 m/z unambiguously confirming the successful synthesis of the water-soluble well-defined bifunctional dendrimer. The cytotoxicity of the well-defined bifunctional triazolylferrocenyl dendrimer 4 was evaluated against MCF-7 (breast adenocarcinoma), HeLa (cervical cancer), PC3 (prostate adenocarcinoma), Caco-2 (colorectal cancer), and PNT2 (normal prostate cells) cell lines. The cytotoxicity assays showed that the dendrimer exhibits moderate anticancer activity and targets cancer cells selectively over normal cells. (AU)

• Processo FAPESP: 17/06146-8 - Desenvolvimento de nanocarregadores baseados em dendrímeros e nanopartículas poliméricas para a vetorização seletiva da goniotalamina, piplartina e monastrol
• Beneficiário: Carolyne Brustolin Braga
• Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado
• Processo FAPESP: 15/04929-0 - Desenvolvimento de biosensores para detecção instantânea de proteínas e de células cancerígenas, para aplicação em biópsias on-site
• Beneficiário: Diego Luan Bertuzzi
• Modalidade de apoio: Bolsas no Brasil - Doutorado Direto
• Processo FAPESP: 21/00555-9 - Desenvolvimento de nanopartículas poliméricas e dendrímeros multifuncionais para vetorização de fármacos
• Beneficiário: Igor Dias Jurberg
• Modalidade de apoio: Auxílio à Pesquisa - Regular